Document Detail


Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm.
MedLine Citation:
PMID:  9055861     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17 beta in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.
Authors:
K Miyagawa; J Rösch; F Stanczyk; K Hermsmeyer
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Nature medicine     Volume:  3     ISSN:  1078-8956     ISO Abbreviation:  Nat. Med.     Publication Date:  1997 Mar 
Date Detail:
Created Date:  1997-04-01     Completed Date:  1997-04-01     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9502015     Medline TA:  Nat Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  324-7     Citation Subset:  IM    
Affiliation:
Oregon Regional Primate Research Center, Oregon 97006, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Coronary Vasospasm / prevention & control*
Drug Therapy, Combination
Estradiol / administration & dosage*
Estrogen Replacement Therapy*
Female
Macaca mulatta
Medroxyprogesterone / administration & dosage*
Ovariectomy
Progesterone / administration & dosage*
Progesterone Congeners / administration & dosage*
Risk Factors
Grant Support
ID/Acronym/Agency:
HD18185/HD/NICHD NIH HHS; HL51723/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Progesterone Congeners; 50-28-2/Estradiol; 520-85-4/Medroxyprogesterone; 57-83-0/Progesterone
Comments/Corrections
Comment In:
Nat Med. 1997 Mar;3(3):273-4   [PMID:  9055848 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome.
Next Document:  Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-a...